HBsAg-positive individuals were excluded from clinical trials of direct-acting antivirals (DAA). The alert to the risk of reactivation of hepatitis B virus (HBV) during hepatitis C virus (HCV) treatment was emitted after DAA came into clinical use. In patients HBsAg negative and anti-HBc positive the risk of reactivation appears to be very low.